Literature DB >> 25425682

Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.

Isabelle Laverdière1, Chantal Guillemette1, Ryad Tamouza2, Pascale Loiseau2, Regis Peffault de Latour3, Marie Robin3, Félix Couture4, Alain Filion4, Marc Lalancette4, Alan Tourancheau1, Dominique Charron2, Gérard Socié3, Éric Lévesque5.   

Abstract

Effective immunosuppression is mandatory to prevent graft-versus-host disease and to achieve a successful clinical outcome of hematopoietic stem cell transplantation. Here we tested whether germline single nucleotide polymorphisms in 20 candidate genes related to methotrexate and cyclosporine metabolism and activity influence the incidence of graft-versus-host disease in patients who undergo stem cell transplantation for hematologic disorders. Recipient genetic status of the adenosine triphosphate-binding cassette sub-family C1 and adenosine triphosphate-binding cassette sub-family C2 transporters, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/ inosine monophosphate cyclohydrolase within the methotrexate pathway, and nuclear factor of activated T cells (cytoplasmic 1) loci exhibit a remarkable influence on severe acute graft-versus-host disease prevalence. Indeed, an increased risk of acute graft-versus-host disease was observed in association with single nucleotide polymorphisms located in 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (hazard ratio=3.04; P=0.002), nuclear factor of activated T cells (cytoplasmic 1) (hazard ratio=2.69; P=0.004), adenosine triphosphate-binding cassette sub-family C2 (hazard ratio=3.53; P=0.0018) and adenosine triphosphate-binding cassette sub-family C1 (hazard ratio=3.67; P=0.0005). While donor single nucleotide polymorphisms of dihydrofolate reductase and solute carrier family 19 (member 1) genes are associated with a reduced risk of acute graft-versus-host disease (hazard ratio=0.32-0.41; P=0.0009-0.008), those of nuclear factor of activated T cells (cytoplasmic 2) are found to increase such risk (hazard ratio=3.85; P=0.0004). None of the tested single nucleotide polymorphisms was associated with the occurrence of chronic graft-versus-host disease. In conclusion, by targeting drug-related biologically relevant genes, this work emphasizes the potential role of germline biomarkers in predicting acute graft-versus-host disease. Further investigations are warranted to improve our understanding of these relationships to personalize immunosuppressive therapy and optimize outcomes. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25425682      PMCID: PMC4803136          DOI: 10.3324/haematol.2014.109884

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  47 in total

Review 1.  New directions in the genomics of allogeneic hematopoietic stem cell transplantation.

Authors:  Charles G Mullighan; Peter G Bardy
Journal:  Biol Blood Marrow Transplant       Date:  2007-02       Impact factor: 5.742

Review 2.  Have we made progress in the management of chronic graft-vs-host disease?

Authors:  Stephanie J Lee
Journal:  Best Pract Res Clin Haematol       Date:  2010-11-02       Impact factor: 3.020

3.  Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia.

Authors:  Kim Robien; Jeannette Bigler; Yutaka Yasui; John D Potter; Paul Martin; Rainer Storb; Cornelia M Ulrich
Journal:  Biol Blood Marrow Transplant       Date:  2006-09       Impact factor: 5.742

Review 4.  Novel strategies for the treatment and diagnosis of graft-versus-host-disease.

Authors:  James L M Ferrara
Journal:  Best Pract Res Clin Haematol       Date:  2007-03       Impact factor: 3.020

Review 5.  Immunobiology of allogeneic hematopoietic stem cell transplantation.

Authors:  Lisbeth A Welniak; Bruce R Blazar; William J Murphy
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

Review 6.  The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.

Authors:  Yehuda G Assaraf
Journal:  Drug Resist Updat       Date:  2006-11-07       Impact factor: 18.500

Review 7.  Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy.

Authors:  Katsuhisa Inoue; Hiroaki Yuasa
Journal:  Drug Metab Pharmacokinet       Date:  2013-11-26       Impact factor: 3.614

8.  ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis.

Authors:  In-Wha Kim; Hwi-yeol Yun; Boyoon Choi; Nayoung Han; Seon-Yang Park; Eun Sook Lee; Jung Mi Oh
Journal:  Clin Ther       Date:  2012-07-13       Impact factor: 3.393

9.  A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation.

Authors:  J Luis Espinoza; Akiyoshi Takami; Katsuya Nakata; Makoto Onizuka; Takakazu Kawase; Hideki Akiyama; Koichi Miyamura; Yasuo Morishima; Takahiro Fukuda; Yoshihisa Kodera; Shinji Nakao
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

10.  Prediction of graft-versus-host disease in humans by donor gene-expression profiling.

Authors:  Chantal Baron; Roland Somogyi; Larry D Greller; Vincent Rineau; Peter Wilkinson; Carolyn R Cho; Mark J Cameron; David J Kelvin; Pierre Chagnon; Denis-Claude Roy; Lambert Busque; Rafick-Pierre Sékaly; Claude Perreault
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.